Mustang Bio (NASDAQ:MBIO – Get Rating) had its price objective lifted by investment analysts at BTIG Research from $4.00 to $20.00 in a research note issued on Friday, The Fly reports. BTIG Research’s price target would suggest a potential upside of 160.76% from the stock’s current price. Several other equities analysts have also commented on […]
Mustang Bio, Inc. (NASDAQ:MBIO – Get Rating) saw a significant decrease in short interest in May. As of May 31st, there was short interest totalling 60,100 shares, a decrease of 38.2% from the May 15th total of 97,200 shares. Based on an average daily trading volume, of 59,000 shares, the short-interest ratio is currently 1.0 […]
Mustang Bio (NASDAQ:MBIO – Get Rating) and Aridis Pharmaceuticals (NASDAQ:ARDS – Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, dividends, analyst recommendations and valuation. Profitability This table compares Mustang Bio and Aridis Pharmaceuticals’ […]
Mustang Bio (NASDAQ:MBIO – Get Rating) and Aridis Pharmaceuticals (NASDAQ:ARDS – Get Rating) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, risk, valuation and earnings. Risk and Volatility Mustang Bio has a beta of […]
Mustang Bio, Inc. (NASDAQ:MBIO – Get Rating) was the recipient of a large growth in short interest in April. As of April 30th, there was short interest totalling 148,900 shares, a growth of 30.6% from the April 15th total of 114,000 shares. Based on an average daily volume of 48,100 shares, the short-interest ratio is […]